Chronic myocardial ischemia treated with autologous stem cells
Phase III clinical study, testing safety and efficacy of targeted intramyocardial delivery of autologous CD34+ cells from mobilized peripheral blood, for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and chronic myocardial ischemia.
The trial will enroll 450 patients in 50 clinical sites in the United States, randomized to three arms: treatment with their own autologous CD34+ stem cells, treatment with placebo (control), or unblinded standard of care.
ClinicalTrials website: http://clinicaltrials.gov/ct2/show/NCT01508910?term=baxter+cardiac&rank=6
Responsible Party: Baxter Healthcare Corporation, USA